Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report) – Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Ventyx Biosciences in a research note issued to investors on Tuesday, January 14th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($1.34) for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Ventyx Biosciences’ current full-year earnings is ($2.09) per share.
Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 target price (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Ventyx Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.
Ventyx Biosciences Trading Up 1.0 %
Ventyx Biosciences stock opened at $1.96 on Thursday. The stock has a fifty day moving average price of $2.28 and a two-hundred day moving average price of $2.28. Ventyx Biosciences has a 52-week low of $1.67 and a 52-week high of $11.48.
Institutional Trading of Ventyx Biosciences
Several hedge funds have recently modified their holdings of VTYX. Palumbo Wealth Management LLC bought a new position in Ventyx Biosciences in the 3rd quarter worth approximately $26,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after buying an additional 5,310 shares during the period. Intech Investment Management LLC bought a new stake in shares of Ventyx Biosciences during the third quarter worth $42,000. The Manufacturers Life Insurance Company raised its position in shares of Ventyx Biosciences by 41.1% during the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after acquiring an additional 7,096 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Ventyx Biosciences during the second quarter valued at $58,000. 97.88% of the stock is owned by institutional investors.
Insider Activity at Ventyx Biosciences
In related news, insider John Nuss sold 13,161 shares of the company’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $2.26, for a total transaction of $29,743.86. Following the transaction, the insider now owns 485,701 shares in the company, valued at $1,097,684.26. This represents a 2.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sheila Gujrathi acquired 130,000 shares of the stock in a transaction on Monday, December 23rd. The stock was bought at an average price of $2.31 per share, with a total value of $300,300.00. Following the transaction, the director now directly owns 130,000 shares in the company, valued at approximately $300,300. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders acquired 630,000 shares of company stock valued at $1,262,415 in the last three months. Corporate insiders own 18.18% of the company’s stock.
About Ventyx Biosciences
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.
Featured Stories
- Five stocks we like better than Ventyx Biosciences
- How to Capture the Benefits of Dividend Increases
- D-Wave’s Stock Springs Back in the Quantum Computing Race
- What is MarketRank™? How to Use it
- 2 Top ETFs to Profit From the Natural Gas Price Surge
- Want to Profit on the Downtrend? Downtrends, Explained.
- Penny Stock BranchOut Food: Why It Won’t Stay Cheap for Long
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.